Approved indications: Methohexital sodium is FDA‑approved as an ultra–short-acting barbiturate anesthetic for induction of anesthesia, for providing anesthesia or deep sedation during short surgical or diagnostic procedures, and for anesthesia during electroconvulsive therapy (ECT), when used by trained professionals with appropriate monitoring and resuscitation equipment.

Off‑label uses: Clinicians may use methohexital off‑label for brief deep sedation during minor procedures or imaging in controlled settings, and in some centers it is used to provoke or localize seizures during epilepsy evaluations; these uses rely on clinical experience and smaller studies rather than large randomized trials.

Efficacy expectations: After an intravenous dose, loss of consciousness typically occurs within about 20–30 seconds and lasts only a few minutes, allowing rapid completion of very short procedures or smooth transition to other anesthetic agents.

Clinical outcomes and comparisons: Recovery of awareness is usually quick, with patients often awake and following commands within minutes, though drowsiness and impaired coordination can last longer; compared with older barbiturates like thiopental, methohexital has a particularly rapid onset and short duration, but newer agents such as propofol are now more commonly used because they generally cause less lingering grogginess and are easier to fine‑tune for many procedures.

General administration: Methohexital sodium is given only by trained professionals via intravenous (IV), intramuscular (IM), or rectal routes in controlled settings with continuous monitoring of breathing, blood pressure, heart rhythm, and oxygen levels; it is not a medication patients self‑administer at home.

Typical adult dosing (IV/IM): For induction of anesthesia in healthy adults, an initial IV dose of about 1–1.5 mg/kg is injected over several seconds, with small supplemental doses titrated to effect for very short procedures; IM dosing uses similar weight‑based amounts but has a slower onset and is less commonly used.

Typical pediatric dosing (rectal and IV): In children, rectal induction often uses a single weight‑based dose (for example, around 20–30 mg/kg of a diluted solution), while IV doses are lower per kilogram than in adults and carefully titrated, with adjustments for age, overall health, and concurrent medicines.

Special dosing instructions: Lower initial doses are generally used in older adults, very ill patients, or those receiving other sedatives or opioids; doses are always individualized based on response rather than fixed schedules, and supplemental oxygen and airway equipment are always kept ready.

Missed doses: Because methohexital is used as one‑time or closely supervised intermittent doses (for example, before each ECT session), any missed or delayed dose should be managed by the treatment team, and patients should not attempt to replace or adjust it themselves.

Overdose: Overdose can quickly lead to profound unconsciousness, loss of protective airway reflexes, severe respiratory depression, and cardiovascular collapse; treatment requires immediate emergency care with airway support, assisted ventilation, intravenous fluids, vasopressors as needed, and monitoring, and poison control centers can provide additional management guidance.

Common side effects: Very common effects during and shortly after dosing include sleepiness, dizziness, slowed thinking, injection‑site pain, coughing or hiccups, brief muscle twitching, and temporary drops in blood pressure or breathing rate; nausea and vomiting may occur as the drug is wearing off.

Serious or rare adverse effects: Methohexital can cause severe respiratory depression or apnea, dangerously low blood pressure, irregular heart rhythms, laryngospasm, prolonged unconsciousness, allergic reactions (including anaphylaxis), paradoxical agitation, or seizures, all of which require immediate medical attention and advanced airway and cardiovascular support.

Warnings and precautions: It should be used with extreme caution or avoided in people with unstable cardiovascular status, severe respiratory disease, acute porphyria, known barbiturate allergy, or uncontrolled seizure disorders unless specifically used in a monitored diagnostic setting; dose reductions and extra monitoring are needed in older adults, people who are frail, or those with significant liver impairment.

Pregnancy and breastfeeding: Like other general anesthetics, methohexital can cross the placenta and may cause newborn respiratory depression if used near delivery, so it is typically reserved for situations where the benefits clearly outweigh risks; barbiturates can appear in breast milk, so timing feeds away from anesthesia and monitoring the infant for unusual sleepiness or breathing problems is recommended.

Relative safety compared with other agents: When administered by trained anesthesia professionals with full monitoring, its overall safety profile is similar to other injectable anesthetics, but it has a narrower margin for spontaneous breathing than lighter sedatives and is now less commonly chosen than agents like propofol because of its potential to trigger seizures and cause more postoperative drowsiness in some patients.

Reporting and information updates: Suspected side effects can be reported to national adverse event reporting systems such as the FDA’s MedWatch program, and up‑to‑date safety information is available in the official prescribing information and professional anesthesia guidelines.

Interactions with other medicines and substances: Methohexital’s sedative and respiratory‑depressant effects are increased when combined with other central nervous system depressants such as opioids, benzodiazepines, other sedatives or anesthetics, certain antihistamines, antipsychotics, and alcohol; long‑term use of enzyme‑inducing drugs like some anticonvulsants or rifampin can alter barbiturate metabolism, while strong enzyme inhibitors may prolong its effects.

Supplements, foods, and alcohol: Herbal products and supplements that cause drowsiness or affect the liver (for example, kava, valerian, or high‑dose St. John’s wort) may add to sedative effects or change metabolism, and alcohol significantly increases the risk of excessive sedation, breathing problems, and unstable blood pressure before and after anesthesia.

Diagnostic and imaging procedures: Methohexital is often used during procedures such as endoscopy, minor surgery, or ECT, and its rapid onset and short duration allow quick neurologic assessments; however, it can affect EEGs and other neurologic tests by suppressing or provoking certain brain wave patterns, which clinicians account for when interpreting results.

Conditions requiring extra caution: Use is higher‑risk in people with severe heart disease, shock, significant blood loss, severe asthma or chronic obstructive pulmonary disease, obstructive sleep apnea, advanced liver dysfunction, or a history of porphyria or barbiturate dependence; doses must be carefully adjusted and alternative agents considered when risks outweigh benefits.

Monitoring needs: Continuous monitoring of breathing, oxygen saturation, blood pressure, and heart rhythm is required during and after dosing, with frequent reassessment of airway patency and level of consciousness until the drug’s effects have clearly worn off.

Q: How fast does methohexital sodium work and how long does it last?
A: After an intravenous dose, you usually fall asleep within about 20–30 seconds, and the deepest effects wear off within a few minutes, although you may feel groggy or unsteady for longer.

Q: Will I feel pain while I am under methohexital anesthesia?
A: Methohexital causes unconsciousness and deep sedation but provides little pain relief by itself, so anesthesiologists usually combine it with pain medicines or local anesthetics to keep you comfortable during procedures.

Q: Is methohexital sodium safe for people with seizures?
A: It can suppress seizures at higher doses but may actually trigger or highlight seizure activity at certain doses, which is sometimes used intentionally in epilepsy testing, so its use in people with seizure disorders is carefully planned and closely monitored by specialists.

Q: Why is methohexital used for electroconvulsive therapy (ECT)?
A: It is popular for ECT because it works very quickly, wears off fast, and allows the brief therapeutic seizure to occur while still providing a short, well‑controlled period of anesthesia.

Q: Can I drive or work after receiving methohexital?
A: You should not drive, operate machinery, make important decisions, or drink alcohol for the rest of the day after receiving methohexital, and you should follow your anesthesia team’s specific instructions about when it is safe to resume normal activities.

Storage: Methohexital sodium is almost always stored and handled only in hospitals or clinics as a controlled substance, kept in locked areas at room temperature and protected from light, away from children and unauthorized access.

Disposal: Any unused vials or prepared solutions are normally disposed of by healthcare staff following controlled-substance and hazardous-waste procedures; if you are ever given any to take home (uncommon), return leftovers to the clinic, hospital, or a drug take-back program rather than throwing them in household trash or wastewater.